Cargando…

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

Effective inactivation of the HER2-HER3 tumor driver has remained elusive because of the challenging attributes of the pseudokinase HER3. We report a structure-function study of constitutive HER2-HER3 signaling to identify opportunities for targeting. The allosteric activation of the HER2 kinase dom...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Marcia R., Ruiz-Saenz, Ana, Peterson, Elliott, Agnew, Christopher, Ayaz, Pelin, Garfinkle, Sam, Littlefield, Peter, Steri, Veronica, Oeffinger, Julie, Sampang, Maryjo, Shan, Yibing, Shaw, David E., Jura, Natalia, Moasser, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889928/
https://www.ncbi.nlm.nih.gov/pubmed/35108525
http://dx.doi.org/10.1016/j.celrep.2021.110291
_version_ 1784661518001897472
author Campbell, Marcia R.
Ruiz-Saenz, Ana
Peterson, Elliott
Agnew, Christopher
Ayaz, Pelin
Garfinkle, Sam
Littlefield, Peter
Steri, Veronica
Oeffinger, Julie
Sampang, Maryjo
Shan, Yibing
Shaw, David E.
Jura, Natalia
Moasser, Mark M.
author_facet Campbell, Marcia R.
Ruiz-Saenz, Ana
Peterson, Elliott
Agnew, Christopher
Ayaz, Pelin
Garfinkle, Sam
Littlefield, Peter
Steri, Veronica
Oeffinger, Julie
Sampang, Maryjo
Shan, Yibing
Shaw, David E.
Jura, Natalia
Moasser, Mark M.
author_sort Campbell, Marcia R.
collection PubMed
description Effective inactivation of the HER2-HER3 tumor driver has remained elusive because of the challenging attributes of the pseudokinase HER3. We report a structure-function study of constitutive HER2-HER3 signaling to identify opportunities for targeting. The allosteric activation of the HER2 kinase domain (KD) by the HER3 KD is required for tumorigenic signaling and can potentially be targeted by allosteric inhibitors. ATP binding within the catalytically inactive HER3 KD provides structural rigidity that is important for signaling, but this is mimicked, not opposed, by small molecule ATP analogs, reported here in a bosutinib-bound crystal structure. Mutational disruption of ATP binding and molecular dynamics simulation of the apo KD of HER3 identify a conformational coupling of the ATP pocket with a hydrophobic AP-2 pocket, analogous to EGFR, that is critical for tumorigenic signaling and feasible for targeting. The value of these potential target sites is confirmed in tumor growth assays using gene replacement techniques.
format Online
Article
Text
id pubmed-8889928
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-88899282022-03-02 Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers Campbell, Marcia R. Ruiz-Saenz, Ana Peterson, Elliott Agnew, Christopher Ayaz, Pelin Garfinkle, Sam Littlefield, Peter Steri, Veronica Oeffinger, Julie Sampang, Maryjo Shan, Yibing Shaw, David E. Jura, Natalia Moasser, Mark M. Cell Rep Article Effective inactivation of the HER2-HER3 tumor driver has remained elusive because of the challenging attributes of the pseudokinase HER3. We report a structure-function study of constitutive HER2-HER3 signaling to identify opportunities for targeting. The allosteric activation of the HER2 kinase domain (KD) by the HER3 KD is required for tumorigenic signaling and can potentially be targeted by allosteric inhibitors. ATP binding within the catalytically inactive HER3 KD provides structural rigidity that is important for signaling, but this is mimicked, not opposed, by small molecule ATP analogs, reported here in a bosutinib-bound crystal structure. Mutational disruption of ATP binding and molecular dynamics simulation of the apo KD of HER3 identify a conformational coupling of the ATP pocket with a hydrophobic AP-2 pocket, analogous to EGFR, that is critical for tumorigenic signaling and feasible for targeting. The value of these potential target sites is confirmed in tumor growth assays using gene replacement techniques. 2022-02-01 /pmc/articles/PMC8889928/ /pubmed/35108525 http://dx.doi.org/10.1016/j.celrep.2021.110291 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Campbell, Marcia R.
Ruiz-Saenz, Ana
Peterson, Elliott
Agnew, Christopher
Ayaz, Pelin
Garfinkle, Sam
Littlefield, Peter
Steri, Veronica
Oeffinger, Julie
Sampang, Maryjo
Shan, Yibing
Shaw, David E.
Jura, Natalia
Moasser, Mark M.
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
title Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
title_full Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
title_fullStr Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
title_full_unstemmed Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
title_short Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
title_sort targetable her3 functions driving tumorigenic signaling in her2-amplified cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889928/
https://www.ncbi.nlm.nih.gov/pubmed/35108525
http://dx.doi.org/10.1016/j.celrep.2021.110291
work_keys_str_mv AT campbellmarciar targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT ruizsaenzana targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT petersonelliott targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT agnewchristopher targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT ayazpelin targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT garfinklesam targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT littlefieldpeter targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT steriveronica targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT oeffingerjulie targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT sampangmaryjo targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT shanyibing targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT shawdavide targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT juranatalia targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers
AT moassermarkm targetableher3functionsdrivingtumorigenicsignalinginher2amplifiedcancers